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This is an integrative literature review with the aim of summarizing the prevention measures and 
treatment of thrombotic obstruction of long-term semi-implanted central venous catheters, in patients 
undergoing hematopoietic stem cell transplantation. The sample consisted of seven studies, being 
two randomized controlled clinical trials, three cohort studies and two case series. Regarding the 
prevention measures, one single study demonstrated effectiveness, which was a cohort study on the 
oral use of warfarin. In relation to the treatment measures, three studies evidenced effectiveness, 
one highlighted the efficacy of streptokinase or urokinase, one demonstrated the benefit of using low-
molecular-weight heparin and the other treated the obstruction with heparin or urokinase. Catheter 
patency research shows a restricted evolution that does not follow the evolution of transplantations, 
mainly regarding nursing care.
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Obstrução trombótica do cateter venoso central em pacientes 
submetidos ao transplante de células-tronco hematopoéticas
Trata-se de revisão integrativa da literatura, cujo objetivo foi sintetizar as medidas de 
prevenção e tratamento da obstrução trombótica no cateter venoso central de longa 
permanência e semi-implantado, em pacientes submetidos ao transplante de células-
tronco hematopoéticas. A amostra foi constituída por sete estudos, sendo dois ensaios 
clínicos controlados randomizados, três estudos de coorte e duas séries de casos. 
Quanto às medidas de prevenção, um único estudo que se mostrou efetivo abordando 
pesquisa de coorte sobre o uso da varfarina oral. Em relação às medidas de tratamento, 
três estudos evidenciaram efetividade: um apontou a eficácia da estreptoquinase ou 
uroquinase, outro estudo mostrou benefício no uso de heparina de baixo peso molecular 
e outro tratou a obstrução com heparina ou uroquinase. Nota-se que a evolução da 
pesquisa referente à perviedade do cateter foi restrita, não acompanhando a evolução 
do transplante, principalmente no que tange aos cuidados de enfermagem.
Descritores: Cateterismo Venoso Central; Transplante de Células-Tronco Hematopoéticas; 
Transplante de Medula Óssea; Trombose.
Obstrucción trombótica del catéter venoso central en pacientes 
sometidos al trasplante de células-tronco hematopoyéticas
Se trata de una revisión integradora de la literatura con objeto de sintetizar las medidas de 
prevención y tratamiento de obstrucción trombótica del catéter venosos central de larga 
permanencia y semi-implantado, en pacientes sometidos al trasplante de célulastronco 
hematopoyéticas. La muestra abarcó a siete estudios: dos ensayos clínicos controlados 
aleatorizados, tres estudios de cohorte y dos series de casos. Respecto a las medidas 
de prevención, fue identificado un único estudio efectivo, uno cohorte sobre el uso de la 
warfarina oral. Sobre las medidas de tratamiento, tres estudios evidenciaron efectividad, 
uno apuntó la eficacia de la estreptoquinasa o uroquinasa, otro mostró beneficio del uso 
de heparina de bajo peso molecular y otro trató la obstrucción con heparina o uroquinasa. 
Se observa que la evolución de la investigación sobre la permeabilidad del catéter fue 
limitada, no acompañando la evolución del trasplante, principalmente respecto a los 
cuidados de enfermería.
Descriptores: Cateterismo Venoso Central; Trasplante de Células Madre Hematopoyéticas; 
Trasplante de Medula Ósea; Trombosis.
Introduction
Hematopoietic stem cell transplantation (HSCT) is 
a relatively new procedure used to treat diseases once 
thought to be incurable, which has significantly changed 
the prognosis of patients with these diseases(1). Upon 
admission to the transplantation unit, each patient is 
subjected to the implantation of a long-term, tunneled, 
semi-implanted central venous catheter (CVC), for the 
initiation of conditioning, with the Hickman catheter still 
the most commonly used(2). Usually, maintaining the 
patency of the CVC is performed by the introduction of 
isotonic saline solution with heparin in a concentration 
ranging from 10UI/ml to 100UI/ml. The most frequent 
adverse reactions related to the use of heparin are 
bleeding, anemia and thrombocytopenia. Clinically 
manifested thrombosis related to the CVC occurs in 03% 
to 38.3% of adult patients, suggesting a frequency from 
0.02 to 0.92 events per 1000 catheter days(3). However, 
when considering objectively diagnosed thrombosis, 
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this complication occurs in between 27% and 66% of 
patients(4).
Infection of the intravascular catheter related 
to the presence of fibrin or intraluminal thrombosis is 
more likely because these substances act as a matrix 
for bacterial adhesion, promoting colonization of the 
catheter(5). Catheter-related thrombosis and infection 
are the most important complications in cancer patients 
that require venous access over a long period(6). Given 
the above, the nursing team should adopt effective 
measures to prevent thrombotic obstruction of the 
catheter. The maintenance of the CVC is crucial to the 
success of the HSCT and, given that the nursing team 
handles the CVC intensely, it is extremely important that 
these professionals comprehend the actions that ensure 
its permanence in situ without causing complications for 
the patient, such as its early removal. From this, interest 
has emerged in the area related to the measures that are 
effective in maintaining the intraluminal patency of the 
CVC in patients undergoing HSCT. The aim of this study 
is to summarize the measures related to the prevention 
and treatment of thrombotic obstructions of the long-
term, semi-implanted CVC in patients undergoing HSCT.
Method
It is an integrative review (IR), developed according 
to the following steps: elaboration of the research 
question, search for primary studies, data extraction, 
evaluation of primary studies, analysis and synthesis 
of the results of the review and presentation of the 
review(7). The development of the research question was 
based on the PICO strategy, in which the P is attributed 
to - patients undergoing HSCT with the use of long-term 
and semi-deployed CVCs, the I to - preventive care and 
treatment of the thrombotic obstruction of the long-
term, semi-deployed CVC, the C to - saline solution flush 
with heparin, and the O to - prevention of thrombotic 
obstruction of the long-term semi-deployed CVC. Thus, 
the question prepared to conduct the IR was: “What 
are the measures for the prevention and treatment 
of thrombotic obstruction related to long-term semi-
implanted central venous catheter in HSCT patients?”
The search for the primary studies was conducted 
in the Lilacs, Cinahl, Medline, Embase and Cochrane 
Library electronic databases, as was the checking of 
the references cited in the primary studies selected. 
The controlled descriptors used in the search were 
bone marrow transplantation or hematopoietic 
stem cell transplantation; catheter delay or central 
venous catheterization; venous thromboembolism; 
complications. Furthermore, to ensure a wide search the 
following keywords were used, which were identified in 
the studies that address the topic of interest: central 
venous catheters or central venous access device or 
central venous line or Hickman catheter; occlusion or 
obstruction; catheter-related thrombosis. The controlled 
descriptors and keywords were used in Portuguese or 
English, depending on the database. The inclusion 
criteria were as follows: articles that addressed the 
prevention and treatment of thrombotic obstruction 
of long-term, semi-implanted CVCs in HSCT patients, 
published in English, Spanish or Portuguese during the 
last 30 years. The exclusion criteria were: articles that 
included different populations of patients with long-
term, semi-implanted CVCs, as well as articles on the 
preclinical phase.
The search and selection of the primary studies 
were conducted in September 2010. A total of 312 
primary studies were identified, of which 55 were pre-
selected by reading their titles and abstracts, with 28 
from Medline, 25 from Embase and of two from Cinahl. 
Of the 55 pre-selected studies, 48 were excluded for the 
following reasons: 31 were duplicates in the database 
and between the databases, eight studied the general 
cancer population, six were unrelated to the theme 
and three studies did not meet the language criteria 
established in the selection. The IR sample consisted 
of seven primary studies. In order to systematize the 
extraction of the data from the articles included in this 
review a validated instrument(8) was used, after approval 
by the authors. The data extraction was performed 
independently by two reviewers, with no divergences 
between them. The final analysis of the results of 
each primary study was conducted with the assistance 
of a statistician. The primary studies were classified 
according to the evidence level, in order to present the 
strength of the evidence of each(9). To evaluation the 
methodological quality of the randomized controlled 
trials (RCTs), Jadad scoring(10) was applied.
Results
As mentioned, the IR sample was composed of 
seven primary studies, with three (43%) published in 
the 1990s and four (57%) between 2000 and 2006. 
Regarding the journals and their impact factor in the 
Journal Citation Reports (JCR), two studies (28%) 
were published in the journal Cancer, with an impact 
factor of 5.418, one (14%) in the journal Bone Marrow 
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Transplantation, impact factor 2.998, one (14%) in the 
American Journal of Hematology, impact factor 2.61, one 
(14%) in the journal Pharmacotherapy, impact factor 
2.726, one (14%) in the European Journal of Cancer, 
impact factor 4.121 and one (14 %) in the Journal of 
Parenteral and Enteral Nutrition, with an impact factor 
of 2.231.
The primary studies were grouped into two themes, 
namely: measures for the prevention of thrombotic 
obstruction (five studies)(5,11-14) and measures for the 
treatment of thrombotic obstruction (three studies)
(14-16). One study(14) was included in the two thematic 
categories because it addressed both the prevention 
and treatment of thrombotic obstruction. In relation to 
the study designs and their evidence levels, two RCTs 
were identified which were classified at evidence level II, 
three cohort studies of evidence level IV and two cases 
series of evidence level VI. The two RCTs presented a 
Jadad score of 02(5) and 03(13), respectively.
The first primary study included in the IR(11) had 
a sample of 382 patients who underwent HSCT, which 
were divided into three groups. The occurrence of 
CVC-related thrombosis was evaluated, with swelling, 
redness of the limb and/or venous engorgement being 
regarded as signs and symptoms of thrombosis. In the 
case of the occurrence of the signs and symptoms, the 
thrombosis was confirmed using Doppler ultrasound. 
The first cohort comprised 161 patients and 163 
catheters, and the patients did not receive prophylaxis. 
In the second cohort 123 patients and 25 catheters 
were evaluated, with these patients receiving 2,850UI/
day subcutaneous nadroparin as prophylaxis, after 
the insertion of the catheter, for a duration of six 
days. The third cohort was formed by 98 patients and 
102 catheters, with prophylaxis of 5,700UI/day of 
subcutaneous nadroparin for a period of 10 days after 
catheter insertion. Among the patients evaluated, 27 
developed signs and symptoms of thrombosis, 10 from 
the first cohort, 10 from the second and seven from 
the third. The occurrence of thrombosis related to the 
catheter was 6.9% and had a mean time of occurrence 
of 22 days after insertion of the CVC (05 to 92 days). 
The incidence of thrombosis was similar in all three 
groups (p=0.58), being higher in the double or triple 
lumen catheters compared to the single lumen catheters 
(9.6 and 3.7% respectively). In this study, nadroparin 
was not recommended as prophylaxis for CVC-related 
thrombosis. One possible explanation for these results 
is the short period of administration of nadroparin, with 
the continuation of this medication for a longer period 
possibly leading to greater effectiveness, although, 
increasing the risk of bleeding. The data suggest that 
the thrombosis was initiated by the insertion of the 
catheter, therefore the use of insertion techniques that 
result in less trauma to the vessel wall might reduce the 
risk of catheter-related thrombosis(11).
One of the RCTs(5) evaluated compared the 
occurrence of thrombosis in patients who took part in 
the control group (n=48) and received heparin (50UI 
in 5ml of saline solution) with those who took part in 
the experimental group (n=52) and received urokinase 
(5,000UI in 2ml of saline solution). In both groups the 
injection of the solution was started 48 hours after the 
insertion of the catheter and was carried out twice a 
week. Signs and symptoms of thrombosis related to the 
Hickman catheter were evaluated, which was defined 
by clinical evidence of the presence of thrombi in the 
region of the catheter and confirmed by ultrasound. 
Among the patients that presented Hickman catheter-
related thrombosis, six belonged to the control group 
and eight to the experimental group. The twice 
weekly injection of urokinase, compared to heparin 
did not reduce complications such as obstruction and 
intraluminal thrombosis related to the CVC, thus, 
the use of urokinase was not recommended for the 
prevention of complications related to the CVC. However, 
in the analysis of the underlying condition for which 
transplantation was indicated, it was found that those 
patients who were affected by solid tumors presented 
a higher incidence of thrombotic complications when 
compared with the onco-hematological conditions(5).
One prospective cohort study(12) examined the 
safety and clinical efficacy of the use of oral warfarin. 
The study was performed with 228 patients, 175 with the 
Nutricath-S catheter (Vygon®) and 53 with the Groshong 
catheter (Bard Access System®). All the patients 
received prophylaxis with oral warfarin (1mg/day) 
started on the day of catheter insertion and interrupted 
when the platelet count went below 50,000/dl. In the 
presence of signs or symptoms related to thrombosis, 
such as edema, redness and/or venous engorgement, 
Doppler ultrasound was performed to confirm the 
venous thromboembolism. Four episodes of thrombosis 
were observed, with three related to the CVC. Of these 
events, two were thrombosis of the subclavian vein 
and one was a thrombosis of the subclavian vein with 
extension to the superior vena cava. The other event, 
considered unrelated, was thrombosis of the saphenous 
vein. Four of the followed patients developed bleeding, 
all with normal International Normalized Ratios. 
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Statistical tests were used to evaluate the impact of the 
variables age, underlying disease, therapeutic regimen, 
number of previous chemotherapies performed and type 
of catheter used, however, no association was found 
between the variables investigated and the occurrence 
of the thrombotic event. It was concluded that the use of 
oral warfarin is safe and effective for use in hematologic 
patients who have undergone HSCT(12).
In one, double-blinded, prospective RCT(13) the 
hypothesis was tested that Lepirudin presents a superior 
effect to that of heparin in preventing the aggregation of 
fibrin in the catheter tip. Another hypothesis investigated 
was that effective anticoagulation would only be 
necessary for a few weeks to prevent the formation 
or long term accumulation of thrombi. This hypothesis 
was based on the fact that Lepirudin is adsorbed to the 
hydrophobic surface of the catheter, possibly leading 
to the maintenance of some anticoagulant activity. The 
sample included 49 adult patients undergoing allogeneic 
or autologous HSCT divided into two groups. The control 
group consisted of 24 patients and received a flush of 
3 ml of heparin, 100UI/ml (300UI), in each lumen of 
the catheter, according to the protocol of the institution. 
The experimental group included 25 patients who 
received a 3ml flush of Lepirudin 100μg/ml (300μg) in 
each lumen of the catheter. After three to four weeks 
all the patients began receiving the heparin flush only. 
The efficacy of the interventions was measured by the 
frequency with which the introduction of alteplase was 
necessary for the treatment of catheter occlusion in the 
first 120 days after insertion. Five (20%) patients in 
the experimental group and three (13%) in the control 
group presented intraluminal obstruction and required 
treatment with alteplase, which resolved seven of the 
eight obstructions. All the obstructions occurred in the 
first 60 days. The use of Lepirudin was not shown to be 
more effective than heparin in preventing intraluminal 
obstruction (p=0.62), which, according to the authors, 
may be related to the conservative dose of Lepirudin 
used. However, it was noted that the use of higher doses 
would be problematic since the excretion of the drug is 
renal and any degree of renal failure could increase the 
level of anticoagulation(13).
One case series(14) included five patients undergoing 
autologous HSCT, with semi-implanted CVCs, who 
presented catheter-related thrombosis. In these 
patients the prevention of thrombosis and obstruction 
of the CVC was performed with an occasional flush of 
5,000UI/ml of heparin. After the confirmation of the 
catheter-related thrombosis, where possible the device 
was removed and the patients received 40 mg of 
subcutaneous enoxaparin twice daily (treatment 1) or an 
intravenous bolus of 5,000UI of unfractionated heparin 
and a further 24,000UI in 24 hours (treatment 2). From 
four to 10 days after the initiation of the therapy the 
heparin was replaced by 40mg of enoxaparin twice 
daily. All the patients received enoxaparin for a period 
of 14 days. Before starting the treatment, the patients 
with signs and symptoms of thrombosis underwent 
contrast venography or ultrasonography to confirm the 
presence of the thrombus and were re-evaluated after 
the treatment using the same diagnostic method. In all 
cases, the catheters were removed, since an alternative 
route of venous access was identified in all patients. 
Three patients received treatment 1 and two patients 
initially received treatment 2. The signs and symptoms of 
thrombosis disappeared from one to four days after the 
beginning of both therapies. The imaging examinations 
were repeated and demonstrated the absence of 
thrombi in three patients and the presence of residual 
thrombi in two. It is reported that despite the small 
number of patients evaluated, enoxaparin is an effective 
and safe method to overcome the problems caused by 
catheter-related thrombosis and it is recommended 
that these data are confirmed by the performance of 
an RCT. The authors also emphasize that low-molecular-
weight heparin results in less hemorrhagic episodes 
than unfractionated heparin because it has no effect on 
the platelets, and that it presents a longer half-life and 
higher bioavailability after subcutaneous injection when 
compared to unfractionated heparin.
Another study(15) aimed to identify the factors 
related to thrombotic complications in the subclavian 
vein due to the insertion of a Hickman catheter and to 
evaluate their treatment measures. The sample consisted 
of 168 patients undergoing HSCT and 49 undergoing 
high dose chemotherapy treatment. When the thrombus 
was confirmed by contrast venography the patients 
received fibrinolytic therapy with streptokinase (5,000 
to 25,000UI/hour) or urokinase (20,000 to 200,000UI/
hour). After the implementation of the intervention a 
complete response was considered when the thrombus 
was no longer observed; a partial response, when there 
was the presence of residual thrombus; and no response 
when the presence of the thrombus prevented the 
infusion of the contrast through the catheter. Thrombosis 
occurred in 23 patients (including eight patients who 
had had the catheter inserted at another institution). Of 
these, 19 thrombotic events occurred in the transplant 
patients, with the difference being significant (p=0.03). 
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Statistical analysis showed a higher rate of thrombosis 
free catheters in patients with platelet counts lower 
than 150, 000/dl. Other factors that may be related to 
the occurrence of thrombosis are the intensity of the 
chemotherapy and the coexistence of two implanted 
catheters, since the length of thrombosis-free time 
was higher in the group of patients who had only one 
catheter implanted. Ten of 23 patients that presented 
catheter-related thrombosis received thrombolytic 
therapy with urokinase or streptokinase. Of these 
ten, seven cases presented a complete response. The 
authors recommend that thrombolytic therapy is used 
for restoration of the catheter function only when it is 
impossible to remove it, with removal the first alternative 
in cases of thrombosis(15).
The final study included in the IR, developed 
in the 1990s(16), evaluated the complications related 
to difficulty of blood aspiration through any lumen of 
the catheter, difficulty in intraluminal fluid infusion, 
accidental displacement, damage to the catheter that 
required repair or another intervention, and catheter 
removal for any reason other than discharge or death. 
The sample consisted of 111 patients undergoing HSCT 
with 143 catheters. The maintenance of the catheters 
was performed using heparin infusion. Clearance was 
performed by injecting 3ml of heparin at a dose of 
1,000UI maintained for between 15 minutes and 24 
hours or 2ml of urokinase (5,000UI/ml) maintained for 
15 to 30 minutes. Following this the reflux of blood from 
the catheter lumens was tested and, in the case of this 
not being successful, the treatment was repeated up to 
three times in four hours in patients with a platelet count 
higher than 20,000 and once every four hours in patients 
with a platelet count lower than 20,000. There were 55 
episodes of no reflux in 37 catheters. Intervention was 
required in 35 of the episodes. In ten of the episodes 
the treatment of choice was the removal of the catheter. 
Among the other 25, six were treated with heparin, 
16 with urokinase, two received treatment with both 
medications and in one case a surgical revision of the 
catheter route was performed. The authors concluded 
that adequate training regarding the management and 
maintenance of the CVC is essential for the early detection 
and intervention regarding abnormalities related to its 
operation. Many of the catheter-related complications 
are reversible, therefore interventions should be tried 
as alternatives prior to the removal of the device. The 
study recommends that clearance of catheters affected 
by thrombotic obstruction is performed with heparin or 
urokinase(16).
Discussion
The tested interventions differed between the 
studies regarding the types of drugs, dosage and route 
of administration. However, the use of heparin was seen 
to be predominant for the prevention and treatment of 
thrombotic obstruction in the long-term catheter. This can 
be attributed to the pharmacological characteristics and 
the low economic cost compared to the other possibilities. 
The catheter management in patients undergoing 
HSCT who develop catheter-related thrombosis is not 
yet standardized. The treatment strategies reported in 
the literature consist of thrombolytic therapy, systemic 
anticoagulation, removal of the catheter or a combination 
of two or more therapeutic modalities. In patients with 
non-hematologic diseases, who are not undergoing 
HSCT and that develop catheter-related thrombosis, the 
treatment of choice is the combination of low-molecular-
weight heparin, followed by administration of an oral 
anticoagulant for three to six months(17).
The occurrence of venous thromboembolism in 
patients with hematological neoplasms has been shown 
to be similar to that observed in patients with solid 
tumors. These patients are known to be at higher risk 
for thrombosis(18). One factor that seems to predispose 
to thrombosis is leukocytosis(19), which is common in 
HSCT patients with onco-hematological diseases. One 
of the commonly used medications in the HSCT units 
intended to prevent intraluminal thrombosis is heparin. 
However, this product may induce thrombocytopenia 
from five to 10 days after the initiation of treatment(20). 
Heparin-induced thrombocytopenia (HIT) can be 
triggered even when used in small quantities(21). Another 
problem is that errors in the dose can cause increased 
risk of bleeding(22). However, heparin is more cost-
effective when compared with other medications used 
in the prevention of thrombotic obstruction, such as 
urokinase(5).
A double blind RCT, showed that alteplase, when 
compared with urokinase, is more effective to perform 
thrombotic clearance of the catheter, 120 minutes 
after the medication infusion(23). Alteplase stimulates 
the conversion of plasminogen to plasmin, resulting in 
local fibrinolysis(24). The efficacy of alteplase in catheter 
clearance is reported in the literature as being from 
87 to 90%(25). After confirmation of the partial or total 
thrombotic obstruction of the CVC the infusion of the 
fibrinolytic agent alteplase is recommended, in a dilution 
of 2mg in 2ml of saline solution, in each catheter lumen, 
to wait for 30 minutes and, if necessary, to repeat 
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the dosage after a period of six to eight hours(26). 
Recombinant urokinase has been studied as a medication 
with potential for the management of obstructed CVCs 
in adults. This medication seems to have better efficacy 
when compared to alteplase, in the first 30 minutes, with 
a mean catheter clearance of 60% in patients. However, 
when taking into consideration the longer intraluminal 
time interval, recombinant urokinase is seen to be less 
effective than alteplase(27).
In one prospective cohort study, 74 cancer patients 
were evaluated regarding the safety and effectiveness of 
the treatment strategy for catheter-related thrombosis. 
To this end, dalteparin (low-molecular-weight heparin) 
was used, followed by the use of oral warfarin for three 
months, without removal of the catheter. According to 
the authors no further episodes of thromboembolism 
occurred and the catheters were not removed(28).
One RCT involving 225 cancer patients using CVC, 
with the majority affected by hematological diseases, 
showed no difference in the occurrence of symptomatic 
thrombosis between the group receiving 1 mg of warfarin 
and the placebo group. A limitation of this study was 
the unexpectedly low incidence of thrombosis, only 11 
symptomatic catheter-related thromboses(29). However, 
the treatment of thrombotic obstruction of the catheter 
is preferable to its removal, because this limits the 
interruption of the therapy, reduces patient trauma and 
reduces costs. The estimated cost for the reinsertion of 
a new intravascular device is US$850-1500, depending 
on the type of catheter, which often exceeds the cost of 
the thrombolytic therapy to restore the patency of the 
catheter(30).
In addition to the measures related to the 
prevention and treatment of the thrombotic obstruction 
of the CVC, it was sought to identify, in the studies 
analyzed, the care that could be adopted by the nursing 
staff to maintain the patency of the CVC, with only the 
importance of training the nursing team mentioned. This 
may have occurred because the majority of the studies 
evaluated were authored by physicians. The use of the 
catheter flush is common to maintain the patency of the 
device, but there are no studies in the literature that 
evaluate this intervention(4). The flush is considered the 
first action to prevent fibrin formation and accumulation 
of drug residuals in the catheter lumen(31). However, it 
is important to preserve the integrity of the catheter 
during the flush procedure and for this it is necessary 
to understand the relationship between the size of the 
syringe and the force applied to the plunger. In some 
cases the obstruction of the CVC is directly attributable to 
an inadequate infusion technique, especially as regards 
the absence or failure of a suitable flush in the lumens 
of the device. Furthermore, an improper disconnection 
procedure of the catheter device without prior clamping 
of the manipulated lumen can create the same effect(32).
One systematic review identified 17 primary studies 
and five clinical guidelines on the use of the heparin 
flush, pressure caps and other interventions to maintain 
the patency of the CVC. The studies included evaluated 
patients who had semi-implanted CVCs, independent 
of the pathology and age. The results showed that the 
evidence for the use of the heparin flush, pressure caps, 
and other interventions, such as the urokinase flush to 
reduce CVC-related thrombotic obstruction, is derived 
from primary studies of low quality. Thus, the authors 
state that the available evidence is insufficient to support 
the clinical practice related to the maintenance of the 
catheter patency(22).
Conclusions
Among the studies that addressed prevention 
measures, only the cohort study in which oral warfarin 
was used from the day of CVC insertion indicated 
effective results in the prevention of obstruction. 
The other studies showed no statistically significant 
difference between the standard treatment and 
intervention tested. Regarding the treatment measures, 
three studies demonstrated effectiveness. One pointed 
out the efficacy of streptokinase or urokinase use, one 
demonstrated benefits in the use of low-molecular-
weight heparin and the other successfully treated the 
obstruction with heparin and urokinase. It was noted 
that the evolution of the studies on the patency of the 
CVC was restricted, not accompanying the evolution of 
the HSCT therapy, especially regarding nursing care, 
as they all deal with medication interventions, without 
addressing the non-medication aspects.
Despite an extensive search, the sample obtained 
was limited. However, the performance of this study 
was considered important since it enabled the mapping 
of the publications related to the topic of interest and 
the recognition of gaps, allowing new studies to be 
proposed that cover the specificities of the clientele 
studied. Additionally, the present study emphasizes the 
low number of studies conducted by nurses, considering 
that the handling and manipulation of the intravascular 
device, as well as the maintenance of the patency 
of the catheter, are priority responsibilities of these 
professionals. The results evidenced indicate the need 
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to conduct studies to test nursing interventions in the 
prevention of catheter-related thrombotic obstruction.
References
1. Santos CLT, Sawada NO, Santos JLF. A avaliação da 
qualidade de vida relacionada à saúde de pacientes 
submetidos ao transplante de células-tronco 
hematopoéticas. Rev. Latino-Am. Enfermagem. nov-dez 
2011;19(6):1322-8.
2. Silveira RCCP, Braga FTMM, Garbin LM, Galvão CM. 
O uso do filme transparente de poliuretano no cateter 
venoso central de longa permanência. Rev. Latino-Am. 
Enfermagem. nov-dez 2010;18(6):1212-20.
3. Verso M, Agnelli G. Venous thromboembolism 
associated with long-term use of central venous 
catheters in câncer patients. J Clin Oncol. 2003 Oct 
1;21(19):3665-75.
4. Gallieni M, Pittiruti M, Biffi R. Vascular acess in oncology 
patients. CA Cancer J Clin. 2008 Nov-Dec;58(6):323-46. 
Epub 2008 Oct 29.
5. Solomon B, Moore J, Arthur C, Prince HM. Lack of 
efficacy of twice-weekly urokinase in the prevention 
of complications associated with Hickman catheters: a 
multicentre randomised comparison of urokinase versus 
heparin. Eur J Cancer. 2001 Dec;37(18):2379-84.
6. Kuter DJ. Thrombotic complications of central 
venous catheters in cancer patients. Oncologist. 
2004;9(2):207-16.
7. Mendes KDS, Silveira RCCP, Galvão CM. Revisão 
integrativa: método de pesquisa para incorporação de 
evidências na saúde e na enfermagem. Texto Contexto 
Enferm. 2008;17(4):758-64.
8. Ursi ES, Galvão CM. Prevenção de lesões de pele no 
perioperatório: revisão integrativa da literatura. Rev. 
Latino-Am. Enfermagem. 2006;14(6):124-31.
9. Melnik BM, Fineout-Overholt E. Making the case for 
evidence-based practice. In: Melnik BM, Fineout-Overholt 
E. Evidence-based practice in nursing & healthcare: a 
guide to Best practice. Philadelphia: Lippincot Williams 
& Wilkins; 2011. p. 3-24.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds 
DJ, Gavaghan DJ, et al. Assessing the quality of reports 
of randomized clinical trials: is blinding necessary? 
Control Clin Trials. 1996 Feb;17(1):1-12.
11. Lagro SW, Verdonck LF, Borel IHR, Dekker AW. No 
effect of nadroparin prophylaxis in the prevention of 
central venous catheter (CVC) associated thrombosis 
in boné marrow transplant recipients. Bone Marrow 
Transplant. 2000 Nov;26(10):1103-6.
12. Magagnoli M, Masci G, Castagna L, Pedicini V, Poretti 
D, Morenghi E, et al. Prophylaxis of central venous 
catheter-related thrombosis with minidose warfarin 
in patients treated with high-dose chemotherapy and 
peripheral-blood stem-cell transplantation: retrospective 
analysis of 228 cancer patients. Am J Hematol. 2006 
Jan;81(1):1-4.
13. Horne MK, McCloskey DJ, Calis K, Wesley R, Childs R, 
Kasten-Sportes C. Use of heparin versus lepirudin flushes 
to prevent withdrawal occlusion of central venous Access 
devices. Pharmacotherapy. 2006 Sep;26(9):1262-7.
14. Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor 
A. Low-molecular-weight heparin for Hickman catheter-
induced thrombosis in thrombocytopenic patients 
undergoing bone marrow transplantation. Cancer. 1992 
Oct 1;70(7):1895-8.
15. Haire WD, Lieberman RP, Edney J, Vaughan WP, 
Kessinger A, Armitage JO, et al. Hickman catheter-
induced thoracic vein thrombosis. Frequency and 
long-term sequelae in patients receiving high-dose 
chemoterapy and marrow transplantation. Cancer. 1990 
Sep 1;66(5):900-8.
16. Ulz L, Petersen FB, Ford R, Blakely W, Bennett C, 
Grimm M, et al. A prospective study of complications 
in Hickman right-atrial catheters in marrow transplant 
patients. J Parenter Enteral Nutr. 1990 Jan-
Feb;14(1):27-30.
17. Karaby O, Yetkin U, Onol H. Upper extremity deep 
vein thrombosis: clinical and treatment characteristics. 
J Int Med Res. 2004 Jul-Aug;32(4):429-35.
18. Falanga A, Barbui T, Rickles FR. Hypercoagulability 
and tissue factor gene upregulation in hematologic 
malignances. Semin Thromb Hemost. 2008 
Mar;34(2):204-10.
19. Stoffel N, Rysler C, Buser A, Gratwohl A, Tsakiris 
DA, Stern M. Leukocyte count and risk of thrombosis 
in patientes undergoing haematopoietic stem cell 
transplantation or intensive chemotherapy. Thromb 
Haemost. 2010 Jun;103(6):1228-32. Epub 2010 Mar 29.
20. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial 
interactions: sepsis, HIT, and antiphospholipid 
syndrome. Hematology. [periódico na Internet]; [acesso 
14 jul 2010]. 2003;(1):497-519. Disponível em: http://
asheducationbook.hematologylibrary.org/content/
vol2003/issue1/
21. Gettings EM, Brush KA, Van Cott EM, Hurford WE. 
Outcome of postoperative critically ill patients with 
heparin-induced thrombocytopenia: an observational 
retrospective case-control study. Crit Care. 
2006;10(6):R161.
812
www.eerp.usp.br/rlae
Rev. Latino-Am. Enfermagem 2012 July-Aug.;20(4):804-12.
22. Mitchell MD, Anderson BJ, Williams K, Umscheid CA. 
Heparin flushing and other interventions to maintain 
patency of central venous catheters: a systematic 
review. J Adv Nurs. 2009 Oct;65(10):2007-21.
23. Haire WD, Deitcher SR, Mullane KM, Jaff MR, 
Firszt CM, Schulz GA, et al. Recombinant urokinase 
for restoration of patency in occluded central venous 
access devices. A double-blind, placebo-controlled Trial. 
Thromb Haemost. 2004 Sep;92(3):575-82.
24. Winger L. Vascular access device thrombosis. Clin J 
Oncol Nurs. 2003 May-Jun;7(3):345-8.
25. Journeycake JM, Buchanan GR. Catheter-
related deep venous thrombosis and other catheter 
complications in children with cancer. J Clin Oncol. 2006 
Oct 1;24(28):4575-80.
26. Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, 
Ribeiro RC, et al. Management of occlusion and thrombosis 
associated with long-term indwelling central venous 
catheters. Lancet. 2009 Jul 11;374(9684):159-69.
27. Deitcher SR, Fraschini G, Himmelfarb J, Schuman 
E, Smith TJ, Schulz GA, et al. Dose ranging trial with 
a recombinant urokinase (urokinase alfa) for occluded 
central venous catheters in oncology patientes. J Vasc 
Interv Radiol. 2004 Jun;15(6):575-80.
28. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, 
Andreou R, Mangel JE, et al. A pilot study of central 
venous catheter survival in cancer patients using low-
molecular-weight heparin (dalteparin) and warfarin 
without catheter removal for the treatment of upper 
extremity deep vein thrombosis (The Catheter Sutdy). J 
Thromb Haemost. 2007 Aug;5(8):1650-3.
29. Couban S, Goobyear M, Burnell M, Dolan S, Wasi P, 
Barnes D, et al. Randomized placebo-controlled study of 
low-dose warfarin for the prevention of central venous 
catheter-associated thrombosis in patients with cancer. 
J Clin Oncol. 2005 Jun 20;23(18):4063-9.
30. Kokotis K. Cost containment and infusion services. 
J Infus Nurs. 2005 May-Jun;28(3 Suppl):S22-32;quiz 
S33-6.
31. Macklin D. Catheter management. Semin Oncol 
Nurs. 2010 May;26(2):113-20.
32. Hadaway LC. Reopen the pipeline for I.V. therapy. 
Nursing. 2005 Aug;35(8):54-61; quiz 61-3.
Received: July 14th 2011
Accepted: Mar. 27th 2012
